Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.3110
-0.0501 (-13.87%)
At close: Jul 21, 2026, 4:00 PM EDT
0.3400
+0.0290 (9.32%)
After-hours: Jul 21, 2026, 7:49 PM EDT
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
995.46K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 29.57M |
| Scinai Immunotherapeutics | 1.21M |
| VivoSim Labs | 131.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
VBIO News
- 1 day ago - World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market - PRNewsWire
- 4 days ago - Valion Bio files to sell 29.41M shares of common stock, warrants - TheFly
- 4 days ago - Valion Bio Registration statement: Registration filing - Filings
- 4 days ago - Valion Bio Proxy statement: Proxy filing - Filings
- 7 days ago - Valion Bio reports continued development of Entolimod program - TheFly
- 7 days ago - Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - PRNewsWire
- 14 days ago - Valion Bio Proxy statement: Proxy filing - Filings
- 26 days ago - AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - PRNewsWire